MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.93 -0.76

Buy Sell

Overview

Share price change

24h

Current

Min

3.73

Max

3.9699999999999998

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+270.45% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	2.1M 231M
Previous open	4.69
Previous close	3.93

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 kwi 2026, 17:26 UTC

Major News Events

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7 kwi 2026, 23:55 UTC

Market Talk

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7 kwi 2026, 23:47 UTC

Market Talk

Major News Events

Market Talk Roundup: Latest on U.S. Politics

7 kwi 2026, 23:47 UTC

Market Talk

Major News Events

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7 kwi 2026, 23:44 UTC

Market Talk

Major News Events

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7 kwi 2026, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

7 kwi 2026, 23:42 UTC

Market Talk

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7 kwi 2026, 23:37 UTC

Market Talk

Major News Events

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7 kwi 2026, 23:15 UTC

Market Talk

Major News Events

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7 kwi 2026, 23:04 UTC

Major News Events

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7 kwi 2026, 23:04 UTC

Major News Events

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7 kwi 2026, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 kwi 2026, 23:03 UTC

Market Talk

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7 kwi 2026, 23:01 UTC

Major News Events

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7 kwi 2026, 22:58 UTC

Major News Events

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7 kwi 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

7 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 kwi 2026, 19:45 UTC

Market Talk

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7 kwi 2026, 19:17 UTC

Major News Events

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7 kwi 2026, 19:16 UTC

Market Talk

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7 kwi 2026, 19:07 UTC

Market Talk

Global Energy Roundup: Market Talk

7 kwi 2026, 19:07 UTC

Market Talk

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7 kwi 2026, 18:41 UTC

Acquisitions, Mergers, Takeovers

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7 kwi 2026, 18:40 UTC

Acquisitions, Mergers, Takeovers

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7 kwi 2026, 18:39 UTC

Acquisitions, Mergers, Takeovers

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7 kwi 2026, 18:24 UTC

Major News Events

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 kwi 2026, 17:08 UTC

Market Talk

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7 kwi 2026, 16:21 UTC

Major News Events

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 kwi 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

270.45% upside

12 Months Forecast

Average 14.67 USD 270.45%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.